Literature DB >> 1315723

[Epstein-Barr virus infection--a lympho- and epitheliotropic infection].

H Näher1, D Petzoldt.   

Abstract

Epstein-Barr virus (EBV) has long been thought to be primarily a B-lymphotropic virus. This tropism becomes obvious in the association of the virus with diseases that become manifest in lymphoproliferative conditions, such as acute infectious mononucleosis or endemic Burkitt's lymphoma. In the course of mononucleosis, however, viraemia cannot be detected and B-lymphocytes infected with EBV in vitro produce only small amounts of the virus. In contrast, recent studies document that EBV replicates in the epithelial cells in the mouth, and pronounced secretion of virus can also be detected. Cells of the basal layer of the epithelium can be infected via the EBV-specific CR2 receptor. Upon mitosis of the cells of the basal layer, EBV genome in episomal form is partitioned to the daughter cell. On the other hand, differentiation and maturation of the epithelial cells is paralleled by active virus production. Thus, there is evidence that the epithelial EBV infection is the main factor in the persistence and production of EBV. Accordingly, the EBV infection of epithelial cells which can result in diseases, seems to be the primary process, leading to the infection of B-lymphocytes and then to other diseases. Diseases associated with infection of epithelial cells by EBV and diseases involving B-lymphocytes are discussed with reference to this idea.

Entities:  

Mesh:

Year:  1992        PMID: 1315723

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  Studies of in vivo distribution of bovine herpesvirus type 4 in the natural host.

Authors:  L Egyed; A Ballagi-Pordány; A Bartha; S Belák
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

2.  PCR studies on the potential sites for latency of BHV-4 in calves.

Authors:  L Egyed; A Bartha
Journal:  Vet Res Commun       Date:  1998-04       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.